An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
An Open-Label, Phase I Clinical Trial of GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T) for the Treatment of Patients With Advanced Hepatocellular Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: YING CHENG
- Phone Number: 86-02031605836
- Email: chengy02@fineimmu.com
Study Locations
-
-
Gaungdong
-
Guangzhou, Gaungdong, China, 510700
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- BINKUI LI, Professor
- Phone Number: 86-02087343114
- Email: libk@sysucc.org.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understand and voluntarily sign the informed consent form prior to participating in any trial-related activities;
- Be between 18 and 75 years of age; gender is not restricted;
- Diagnosed with hepatocellular carcinoma (HCC) based on histopathological or cytological examination: Patients classified as inoperable Stage IIa, IIb, IIIa, or IIIb according to the Chinese National Liver Cancer (CNLC) staging system, or Stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system, or Stage B patients who are inoperable or unsuitable for local treatment; Child-Pugh liver function score ≤ 7;
- Previous failure of or intolerance to at least two lines of standard systemic therapy;
- The subject must provide a tumor sample or biopsy specimen collected within the past 2 years that meets the requirements and tests positive for GPC3 expression via immunohistochemistry;
- At least one measurable lesion according to RECIST 1.1 criteria;
- ECOG performance status of 0-1;
- Expected survival of more than 3 months;
- Echocardiography showing a left ventricular ejection fraction (LVEF) ≥50%;
Laboratory test results must meet at least the following criteria:
ANC ≥1.0×10⁹/L; PLT ≥75×10⁹/L; Hb ≥ 75 g/L; Creatinine clearance ≥ 60 mL/min; AST ≤ 5×ULN; ALT≤ 5×ULN; TBIL ≤ 3×ULN;
- If HBsAg-positive or HBcAb-positive, HBV-DNA must be ≤ 2000 IU/mL;
- Women of childbearing potential must have a negative pregnancy test prior to receiving study treatment; they must agree to use effective contraception during treatment.
Exclusion Criteria:
- The subject has undergone major surgery within 2 weeks prior to apheresis, or is expected to undergo major surgery during the trial;
- The subject is allergic to any component of the drugs to be used in this study, including but not limited to cyclophosphamide, fludarabine, CAR-T products, or their excipients;
- Has not recovered from adverse reactions related to prior surgery or treatment to Grade ≤ 2; exceptions include alopecia, hyperpigmentation, and other conditions deemed by the investigator not to affect the subject's tolerability;
- Has a clinically significant central nervous system (CNS) disorder (e.g., epilepsy, severe cerebrovascular stenosis) or other diseases presenting with significant neurological symptoms (including psychiatric disorders);
- Received radiotherapy, systemic chemotherapy, or immune checkpoint inhibitors for the study disease within 2 weeks prior to apheresis; or received small-molecule targeted therapies such as sorafenib, regorafenib, or lenvatinib within 1 week prior to apheresis;
- Received systemic glucocorticoid therapy within 7 days prior to single-plasma donation; patients currently using or who have recently used inhaled or topical glucocorticoids, as well as those on physiological-dose replacement therapy, are eligible for enrollment;
- Any uncontrolled active infection, including but not limited to active tuberculosis or infectious diseases requiring systemic treatment;
- Known active autoimmune diseases, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, multiple sclerosis, and glomerulonephritis (patients with vitiligo are not excluded);
- History of organ transplantation, autologous/allogeneic stem cell transplantation, or renal replacement therapy;
- HCV antibody-positive with HCV RNA levels above the lower limit of detection; HIV antibody-positive; syphilis antibody-positive;
- Currently pregnant or breastfeeding, or planning to become pregnant during the study;
- Participants deemed by the investigator to be unable or unwilling to comply with the requirements of the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose escalation was performed in a 3+3 design
The Super CAR-T dose toxicity test was escalated according to the following dose (positive cells) escalation schedule: Level 1 Level 2 Level 3
|
All participators received lymphoid-depleted preconditioning before Super CAR-T cells infusion. Super CAR-T cells were infused 3 days later. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose Limiting Toxicity (DLT)
Time Frame: 28 days after cell infusion
|
Determining the DLT of Super CAR-T adoptive Immunotherapy.
|
28 days after cell infusion
|
|
Maximum Tolerated Dose (MTD)
Time Frame: 28 days after cell infusion
|
Determining the MTD of Super CAR-T adoptive Immunotherapy.
|
28 days after cell infusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate(ORR)
Time Frame: Research period
|
ORR defined as the proportion of subjects with a confirmed PR or better best response.
|
Research period
|
|
Progression Free Survival(PFS)
Time Frame: One year after cell infusion
|
PFS defined the time from the subject's treatment to the occurrence of PD or death from any cause, whichever occurred first.
If no event (PD or death) occurred, the date of the last response assessment was the censored time for PFS.
|
One year after cell infusion
|
|
Overall Survival (OS)
Time Frame: One year after cell infusion
|
OS defined time from subject's treatment to death.
Participants with no death recorded at the time of statistical analysis were censored at the time of the last follow-up.
In cases of loss to follow-up, data were censored at the date of the last contact with the participant.
|
One year after cell infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: BINKUI LI, Professor, Sun Yat-sen University Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FIT004-IIT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.